Fredun Pharmaceuticals launches premium hormone range products targeting longevity and human performance therapeutics.
The strategic expansion combines clinical credibility with a digital-first patient engagement ecosystem for high-margin segments.
Initial portfolio includes testosterone-based therapies, nandrolone, and growth hormone-oriented solutions under medical supervision.
Company reported FY25 revenues of ₹456 Cr with EBITDA of ₹55 Cr and PAT of ₹21 Cr.